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ABSTRACT
Objective: Mucosal infections including vulvovaginal candidiasis are a common problem for women
with human immunodeficiency virus (HIV) infection. Our objective was to determine which fac-
tors predict the development of symptomatic disease among HIV-infected women.
Materials and Methods: In a prospective study from 1991 to 1995, 205 HIV-positive women were
evaluated every 6 months for occurrences of vulvovaginal candidiasis. Included in the study were
all initially asymptomatic women, whether they were fungal-culture-positive or -negative at base-
line. Excluded from the study were all women with symptomatic vulvovaginal candidiasis at the
initial visit, those who developed trichomonas vaginitis at any visit, and those who used any anti-
fungal agents.
Results: The risk of the development of vulvovaginal candidiasis did not differ between women
who were asymptomatically colonized at baseline and those who were fungal-culture-negative.
However, the risk of developing vulvovaginal candidiasis was increased 6.8 times for women with
CD4 counts less than 200 cells/mm3 at baseline.
Conclusions: Fungal culture is not predictive of the development of symptomatic vulvovaginal
candidiasis. Women infected with HIV who have CD4 counts below 200 cells/mm3 should be
monitored more carefully for vulvovaginal candidiasis. Infect. Dis. Obstet. Gynecol. 8:176-180,
2000. (C) 2000 Wiley-Liss, Inc.
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ulvovaginal candidiasis, although not consid-
ered a defining illness of acquired immune de-
ficiency syndrome (AIDS), is categorized by the
Centers for Disease Control’s classification system
for human immunodeficiency virus (HIV) infection
as a condition whose course or management may be
altered by HIV infection. Several studies have re-
ported that vaginal candidiasis among HIV-positive
women occurs frequently and is due primarily to
Candida albicans and Torulopsis glabrata. De-
pressed T-cell function due to drugs or immuno-
logical or systemic disease is a well-recognized fac-
tor predisposing to either local or diffuse mucosal
candidiasis, and cell-mediated immunity depres-
sion correlates well with the occurrence of local or
systemic candidal infection,e The prevalence of
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the infection has been related to the immune status
of HIV-infected women.
Not all authors have found the same relationship
between HIV infection and vulvovaginal candidia-
sis.3 Some have suggested that vaginal candidiasis
is not an AIDS-related illness and that the initial
studies overestimated its importance among HIV-
infected women because of bias in those studies
related to the failure to include community con-
trols. However, most authors have found some in-
crease in the prevalence of colonizatio’n and dis-
ease, particularly among those whose CD4 counts
are at the lower extremes, z,4
Although several authors have reported the
prevalence of vulvovaginal candidiasis, less is
known about the incidence and the determinants
of symptomatic disease. In an earlier report from
the cohort described here, we noted that the inci-
dence of many gynecologic conditions, including
Candida, is increased among HIV-infected women.
However, the relative contribution of colonization
and immune status to incident cases of vulvovagi-
nal candidiasis was not assessed.
Since vulvovaginal candidiasis is a common
problem for HIV-positive women, we report here
the results of a prospective study of a cohort of
HIV-positive women to determine the incidence,
and the risk factors associated with the develop-
ment, of that condition.
SUBJECTS AND METHODS
From September 1991 through July 1995, a total of
205 HIV-positive women were enrolled in a pro-
spective study of the natural history of HIV disease
in women and 197 were available for follow-up. At
6-month intervals, a gynecologic exam was per-
formed, and demographic, behavioral, and clinical
variables were assessed. The examinations in-
cluded fungal cultures. Fungal cultures were col-
lected as follows: a sterile cotton-tipped swab was
inserted into the introitus and inoculated onto a
plate containing bismuth sulfite-glucose-glycine-
yeast medium (Remel, Lenexa, KS). The cultures
were incubated at 35C and examined daily. Cul-
tures were considered negative when there was no
evidence of growth after 7 days of incubation.
Yeasts were identified using standard mycologic
procedures, including gram staining, germ tube for-
mation, and the API 20C system (Analytab Prod-
ucts, Inc., Plainview, NY) for biochemical reac-
tions. Vulvovaginal candidiasis was defined as the
presence of C. albicans on culture in addition to
self-reported symptoms of vaginal burning, itching,
or abnormal discharge. Patients were asked about
interval visits for candidal symptoms or discharge.
Specimens for Trichomonas vaginalis were collected
with calcium alginate swabs, placed in tubes of
modified Diamond’s medium (Remel), and incu-
bated at 35C _+ lC for up to 7 days. These cul-
tures were examined daily by wet mount (110x) for
the presence of typical motile trichomonads, as
previously described,s Enumeration of T-cell sub-
sets by flow cytometry using monoclonal antibod-
ies (Becton Dickinson, San Jose, CA) was done at
an ACTU certified laboratory at each study visit.
Serologic status for syphilis was assessed using the
rapid plasma reagin test (RPR) and confirmed by
the Treponema pallidum hemagglutination assay
(TPHA).
To focus on incident cases, data were analyzed
for: 1) women with a positive culture for Candida
but lacking vaginal symptoms at the time of enroll-
ment and 2) women with a negative culture for
Candida at the time of enrollment. Symptomatic
women who were culture-positive at enrollment
were excluded from analysis. Women who had
trichomonal vaginitis at any follow-up visit or who
reported use of antifungal agents since the prior
follow-up were also excluded.
Comparisons between proportions were by
Fisher exact test. The probability of developing
vulvovaginal candidiasis was estimated by the
Kaplan-Meier method. The probability of vulvo-
vaginal candidiasis occurrence adjusted for other
variables was determined by Cox proportional haz-
ard model. Results were considered statistically
significant at P < 0.05. In regard to power consid-
erations, overall, there was a 20% chance of devel-
oping vulvovaginal candidiasis during the 2.5-year
study period. With the present sample size, there
was a 74% chance of detecting a two-fold or greater
difference in the relative risk between the asymp-
tomatic and negative-culture women.
RESULTS
As noted, all symptomatic women with positive
candidal cultures (n 30) and those who developed
trichomonas vaginitis during follow up (n 6) or
received antifungal medications in the prior 6
months (n 34) were excluded from analysis. One
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TABLE I. Characteristics of Candida-colonized and
noncolonized HIV-infected women
Noncolonized Colonized
N 130 N 21 P-value
Age (y) 33.2 + 7.7 33. + 10. 0.94
Ethnicity (%)
Hispanic 22.3 23.8
Black 70.8 71.4 0.93
White 6.9 4.8
CD4 group (%)
<200 cells/mm II .5 4.8
200-499 cells/mm 56.2 52.4 0.24
500+ cells/mm 32.3 42.9
Syphilis serology
reactivity (%) 15.5 33.3 0.06
TABLE 2. Risk of incident vulvovaginal candidiasis in
130 women culture-negative at onset and 21
women culture-positive at onset
95%
Relative confidence
Variable risk P-value interval
Age (y) 0.92 0.07 0.84-1.01
History of prior antibiotic use 2.18 0.12 0.82-5.81
Group (asymptomatic vs.
culture-negative) 0.74 0.69 0.16-3.35
Positive RPR 4.18 0.01 1.45-12.00
CD4 group
<200 vs. >500 cells/mm 8.20 0.02 1.32-50.89
200-499 vs. >500 cells/mm 1.62 0.37 0.57-4.64
hundred and thirty women who were asymptomat-
ic and were Candida-culture-negative and 21
asymptomatic culture-positive women were in-
cluded in the analysis. The mean age for both
groups was 33 years, with no significant differences
in ethnicity or CD4 counts (Table 1).
Of the 130 asymptomatic culture-negative
women, 18 developed at least one episode of vul-
vovaginal candidiasis over the 2.5-year follow-up,
and of the 21 asymptomatic culture-positive
women, two developed at least one episode of vul-
vovaginal candidiasis over the 2.5-year follow-up.
There was no difference between the two groups
in the frequency of interval visits for Candida-
related symptoms or discharge. The average length
of follow up for each group was year. There was
not a significant difference in the incidence of vul-
vovaginal candidiasis between the two groups (P <
0.8). After the culture-positive and culture-
negative groups were adjusted for age, prior anti-
biotic use, syphilis reactivity (TPHA), and CD4
group, there was still no significant difference be-
tween the incidence of vulvovaginal candidiasis in
the two groups (P < 0.45).
The two groups were then combined and the
relative risks of vulvovaginal candidiasis were then
determined in relation to prior positive RPR, prior
antibiotic use, and age (Table 2). The history of
prior reactive syphilis serology increased the rela-
tive risk of developing vulvovaginal candidiasis by
4.1 times (P 0.01). A history of prior antibiotic use
since last visit increased the relative risk of vulvo-
vaginal candidiasis 2.2 times (P 0.12). After ad-
justing for age, prior antibiotic use, and syphilis
serology, the relative risk of vulvovaginal candidi-
asis was 8.2 times greater for women with a CD4
count less than 200 cells/mm3 (P 0.02) (Figure 1).
The risk of vulvovaginal candidiasis among women
with a CD4 counts less than 200 cells/mm3 re-
mained eight times greater in a model stratified by
the initial culture status.
DISCUSSION
We have found that an HIV-infected woman’s im-
mune status is a more important determinant of the
subsequent occurrence of vulvovaginal candidiasis
than is vaginal culture status at baseline. These
findings may have important implications for the
monitoring and care of HIV-infected women.
A number of prior studies have reported on the
prevalence of, and risk factors for, candidiasis in
HIV-positive women. Early in the AIDS epidemic,
Rhoads et al. studied 29 HIV-positive women at
the Walter Reed Army Medical Center and re-
ported that in 24% chronic candidal vaginitis was
the presenting complaint and that it predated the
occurrence of oral thrush.6 They suggested that in
these circumstances vulvovaginal candidiasis might
be the only clinical indication of severe underlying
immunodeficiency.
Spinillo et al. prospectively studied 84 HIV-
positive women and 384 HIV-negative controls and
found a prevalence of vaginal candidiasis of 61.9%
among the HIV-positive women and 32.3% in the
control group,z They also determined that after
treatment of the vaginal infection, the time to re-
currence was significantly shorter in HIV-positive
patients than in controls and that the time interval
correlated with the severity of immunosuppression.
Imam et al. studied 66 HIV-positive women
over a 3-year period and demonstrated that Candida
often infected the vaginal mucosa before there was
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Fig. I. Observed probability of developing vulvovaginal candidiasis by CD4 group (n 15 I), adjusted for age, history of prior
antibiotic use, and syphilis serology.
a significant reduction in CD4 counts.4 However,
candidal infection of the oropharynx was associated
with highly significant reductions in the CD4
count.
More recently, in a previous study of this cohort,
it was found that 81 of 223 (36%) HIV-infected
women without AIDS-defining conditions and 72
of 289 (25%) HIV-uninfected women were culture-
positive for vaginal candidiasis. It was concluded
that among HIV-positive women, risks for coloni-
zation were increased approximately threefold in
women with CD4 counts below 200 cells/mm3
compared with either immunocompetent HIV-
infected or HIV-uninfected women. Another re-
port from this cohort noted that HIV-infected
women were also significantly more likely to have
symptomatic candidiasis (odds ratio 1.80; 95%
confidence interval, 1.0-3.25; P 0.05). 7
Although many authors have reported on the
prevalence of colonization and disease, few have
assessed incidence. A previous study that included
some of the same women assessed here, did report
the incident rate of candidiasis along with many
other gynecologic conditions. 7 However, there was
no careful assessment of factors associated with in-
cident vulvovaginal candidiasis.
In the current analysis we have found a 9% an-
nual incidence of at least one episode of vulvovagi-
nal candidiasis among HIV-positive women. There
was no significant difference in the incidence of vul-
vovaginal candidiasis between HIV-infected women
who were asymptomatic and fungal-culture-positive
and HIV-infected women who were asymptomatic
and fungal-culture-negative, even when adjusting
for confounding factors such age, antibiotic use,
history of positive RPR, and CD4 count. The as-
sociation noted with RPR status might reflect small
sample size, differences in sexual histories, or a
relationship between immune status and RPR sta-
tus. However, for HIV-positive women with a CD4
count less than 200 cells/mm3, there was an in-
crease of 8.2 times in the incidence of vulvovaginal
candidiasis.
The finding that low CD4 count was more
closely associated with the subsequent develop-
ment of vulvovaginal candidiasis than was coloni-
zation with Candida suggests that it would be more
appropriate to base monitoring protocols on im-
mune status than on colonization status. Thus, put-
ting an asymptomatic woman with a relatively high
CD4 count who is colonized with Candida on pro-
phylactic medications would not seem warranted
by these data. Conversely, women with low CD4
counts should be closely monitored for the devel-
opment of vulvovaginal candidiasis prior to the de-
velopment of symptoms independent of coloniza-
tion status.
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